The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
Endometrial cancer is one of the most common cancers of the reproductive organ in women. The incidence of it increases from year to year. In our study we assessed role of FGF21 and FGF23 in the diagnostics of patients with endometrial cancer. The study involved 182 patients, who were undergoing abra...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/10/6/414 |
| _version_ | 1827714781698588672 |
|---|---|
| author | Aneta Cymbaluk-Płoska Paula Gargulińska Anita Chudecka-Głaz Sebastian Kwiatkowski Ewa Pius-Sadowska Bogusław Machaliński |
| author_facet | Aneta Cymbaluk-Płoska Paula Gargulińska Anita Chudecka-Głaz Sebastian Kwiatkowski Ewa Pius-Sadowska Bogusław Machaliński |
| author_sort | Aneta Cymbaluk-Płoska |
| collection | DOAJ |
| description | Endometrial cancer is one of the most common cancers of the reproductive organ in women. The incidence of it increases from year to year. In our study we assessed role of FGF21 and FGF23 in the diagnostics of patients with endometrial cancer. The study involved 182 patients, who were undergoing abrasion due to perimenopausal bleeding. FGF21, FGF23, and leptin concentration were quantified in serum by multiplex fluorescent bead-based immunoassays (Luminex Corporation). The median of FGF21 protein (181.8 pg/mL) as well as leptin (16.9 ng/mL) in patients with endometrial cancer was statistically significant higher compared to median of those proteins among patients from control group (152.1 pg/mL and 14.1 ng/mL, respectively). However, no significant differences were found in these groups at median FGF23 concentrations. For FGF21 and leptin, the AUC values were 0.81/0.79, while FGF23, the AUC values was 0.66 for all study patients. Leptin and FGF21 concentrations were statistically significantly higher in patients with poorly differentiated G3 tumors compared to patients with moderately differentiated G2 tumors and with moderately differentiated G2 with highly differentiated G1 respectively: <i>p</i> = 0.02/<i>p</i> = 0.03 and <i>p</i> = 0.02/<i>p</i> = 0.005. FGF21 appears to be useful as a diagnostic as well as prognostic factor in patients with endometrioid endometrial carcinoma. |
| first_indexed | 2024-03-10T19:05:19Z |
| format | Article |
| id | doaj.art-a93974fe78ae4afbb762c5076173bc32 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T19:05:19Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-a93974fe78ae4afbb762c5076173bc322023-11-20T04:11:44ZengMDPI AGDiagnostics2075-44182020-06-0110641410.3390/diagnostics10060414The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer PatientsAneta Cymbaluk-Płoska0Paula Gargulińska1Anita Chudecka-Głaz2Sebastian Kwiatkowski3Ewa Pius-Sadowska4Bogusław Machaliński5Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, PolandDepartment of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, PolandDepartment of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, PolandDepartment of Obstetrics and Gynecology, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, PolandGeneral Pathology Department, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, PolandGeneral Pathology Department, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, PolandEndometrial cancer is one of the most common cancers of the reproductive organ in women. The incidence of it increases from year to year. In our study we assessed role of FGF21 and FGF23 in the diagnostics of patients with endometrial cancer. The study involved 182 patients, who were undergoing abrasion due to perimenopausal bleeding. FGF21, FGF23, and leptin concentration were quantified in serum by multiplex fluorescent bead-based immunoassays (Luminex Corporation). The median of FGF21 protein (181.8 pg/mL) as well as leptin (16.9 ng/mL) in patients with endometrial cancer was statistically significant higher compared to median of those proteins among patients from control group (152.1 pg/mL and 14.1 ng/mL, respectively). However, no significant differences were found in these groups at median FGF23 concentrations. For FGF21 and leptin, the AUC values were 0.81/0.79, while FGF23, the AUC values was 0.66 for all study patients. Leptin and FGF21 concentrations were statistically significantly higher in patients with poorly differentiated G3 tumors compared to patients with moderately differentiated G2 tumors and with moderately differentiated G2 with highly differentiated G1 respectively: <i>p</i> = 0.02/<i>p</i> = 0.03 and <i>p</i> = 0.02/<i>p</i> = 0.005. FGF21 appears to be useful as a diagnostic as well as prognostic factor in patients with endometrioid endometrial carcinoma.https://www.mdpi.com/2075-4418/10/6/414FGF21FGF23leptinendometrial cancerobesity |
| spellingShingle | Aneta Cymbaluk-Płoska Paula Gargulińska Anita Chudecka-Głaz Sebastian Kwiatkowski Ewa Pius-Sadowska Bogusław Machaliński The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients Diagnostics FGF21 FGF23 leptin endometrial cancer obesity |
| title | The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
| title_full | The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
| title_fullStr | The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
| title_full_unstemmed | The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
| title_short | The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients |
| title_sort | suitability of fgf21 and fgf23 as new biomarkers in endometrial cancer patients |
| topic | FGF21 FGF23 leptin endometrial cancer obesity |
| url | https://www.mdpi.com/2075-4418/10/6/414 |
| work_keys_str_mv | AT anetacymbalukpłoska thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT paulagargulinska thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT anitachudeckagłaz thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT sebastiankwiatkowski thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT ewapiussadowska thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT bogusławmachalinski thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT anetacymbalukpłoska suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT paulagargulinska suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT anitachudeckagłaz suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT sebastiankwiatkowski suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT ewapiussadowska suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients AT bogusławmachalinski suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients |